Eton Pharmaceuticals (ETON) Competitors $17.32 +0.27 (+1.58%) Closing price 08/12/2025 04:00 PM EasternExtended Trading$17.01 -0.31 (-1.78%) As of 08/12/2025 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ETON vs. EWTX, BHVN, MENS, SDGR, DYN, EVO, JANX, TVTX, ANIP, and AUPHShould you be buying Eton Pharmaceuticals stock or one of its competitors? The main competitors of Eton Pharmaceuticals include Edgewise Therapeutics (EWTX), Biohaven (BHVN), Jyong Biotech (MENS), Schrodinger (SDGR), Dyne Therapeutics (DYN), Evotec (EVO), Janux Therapeutics (JANX), Travere Therapeutics (TVTX), ANI Pharmaceuticals (ANIP), and Aurinia Pharmaceuticals (AUPH). These companies are all part of the "pharmaceutical products" industry. Eton Pharmaceuticals vs. Its Competitors Edgewise Therapeutics Biohaven Jyong Biotech Schrodinger Dyne Therapeutics Evotec Janux Therapeutics Travere Therapeutics ANI Pharmaceuticals Aurinia Pharmaceuticals Edgewise Therapeutics (NASDAQ:EWTX) and Eton Pharmaceuticals (NASDAQ:ETON) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership. Which has more risk & volatility, EWTX or ETON? Edgewise Therapeutics has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500. Comparatively, Eton Pharmaceuticals has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500. Do institutionals & insiders have more ownership in EWTX or ETON? 27.9% of Eton Pharmaceuticals shares are held by institutional investors. 23.2% of Edgewise Therapeutics shares are held by insiders. Comparatively, 14.9% of Eton Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media prefer EWTX or ETON? In the previous week, Edgewise Therapeutics had 9 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 17 mentions for Edgewise Therapeutics and 8 mentions for Eton Pharmaceuticals. Edgewise Therapeutics' average media sentiment score of 0.40 beat Eton Pharmaceuticals' score of -0.06 indicating that Edgewise Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Eton Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is EWTX or ETON more profitable? Edgewise Therapeutics has a net margin of 0.00% compared to Eton Pharmaceuticals' net margin of -7.10%. Eton Pharmaceuticals' return on equity of -0.73% beat Edgewise Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Edgewise TherapeuticsN/A -30.65% -29.18% Eton Pharmaceuticals -7.10%-0.73%-0.22% Do analysts recommend EWTX or ETON? Edgewise Therapeutics presently has a consensus price target of $41.60, indicating a potential upside of 210.68%. Eton Pharmaceuticals has a consensus price target of $29.67, indicating a potential upside of 71.29%. Given Edgewise Therapeutics' higher possible upside, research analysts clearly believe Edgewise Therapeutics is more favorable than Eton Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Edgewise Therapeutics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.90Eton Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger earnings & valuation, EWTX or ETON? Eton Pharmaceuticals has higher revenue and earnings than Edgewise Therapeutics. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Edgewise Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEdgewise TherapeuticsN/AN/A-$133.81M-$1.55-8.64Eton Pharmaceuticals$39.01M11.91-$3.82M-$0.16-108.25 SummaryEdgewise Therapeutics and Eton Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks. Get Eton Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ETON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ETON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ETON vs. The Competition Export to ExcelMetricEton PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$457.24M$2.99B$5.49B$9.69BDividend YieldN/A2.29%4.64%4.14%P/E Ratio-108.2519.9630.4025.31Price / Sales11.91344.97444.45101.55Price / CashN/A40.7837.7258.50Price / Book19.467.658.306.01Net Income-$3.82M-$54.75M$3.26B$265.10M7 Day Performance13.50%0.95%1.53%1.39%1 Month Performance19.53%8.12%3.73%2.43%1 Year Performance359.42%10.97%41.02%24.74% Eton Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ETONEton Pharmaceuticals2.0023 of 5 stars$17.32+1.6%$29.67+71.3%+361.9%$457.24M$39.01M-108.2520Earnings ReportEWTXEdgewise Therapeutics1.9595 of 5 stars$13.61-4.9%$40.55+197.9%-21.5%$1.51BN/A-8.7860Earnings ReportAnalyst RevisionBHVNBiohaven3.1771 of 5 stars$14.70-0.1%$58.46+297.8%-63.6%$1.50BN/A-1.57239Trending NewsEarnings ReportUpcoming EarningsAnalyst ForecastMENSJyong BiotechN/A$23.46+22.7%N/AN/A$1.45BN/A0.0031News CoverageGap DownSDGRSchrodinger2.978 of 5 stars$19.99+2.4%$32.75+63.8%+1.2%$1.43B$207.54M-7.60790Earnings ReportAnalyst RevisionDYNDyne Therapeutics3.7234 of 5 stars$10.25+2.0%$36.25+253.7%-73.0%$1.43BN/A-2.66100Gap UpEVOEvotec2.3272 of 5 stars$3.88-3.5%$5.90+52.1%+28.3%$1.43B$862.40M0.004,827JANXJanux Therapeutics2.6457 of 5 stars$23.91+1.5%$91.89+284.3%-33.7%$1.39B$9.34M-17.5830Earnings ReportAnalyst RevisionTVTXTravere Therapeutics2.0106 of 5 stars$15.96+2.1%$32.14+101.4%+99.0%$1.39B$233.18M-5.68460Earnings ReportAnalyst ForecastAnalyst RevisionANIPANI Pharmaceuticals3.2326 of 5 stars$65.43+2.3%$78.88+20.5%+48.0%$1.38B$614.38M-51.52600Earnings ReportAnalyst ForecastAUPHAurinia Pharmaceuticals2.3683 of 5 stars$11.45+9.2%$12.00+4.8%+107.3%$1.38B$235.13M26.63300Positive NewsHigh Trading Volume Related Companies and Tools Related Companies EWTX Alternatives BHVN Alternatives MENS Alternatives SDGR Alternatives DYN Alternatives EVO Alternatives JANX Alternatives TVTX Alternatives ANIP Alternatives AUPH Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ETON) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredNew Federal Land Rush About to Start?A $100 Trillion Wealth Shift Is Already Underway Lithium. Oil. Gold. Trillions in U.S. resources are being ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eton Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eton Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access